Document Detail

Learning from an epidemiological, population-based study on prescribed medicine use in adults.
MedLine Citation:
PMID:  23335093     Owner:  NLM     Status:  Publisher    
OBJECTIVE: The aim of this study was to examine changes in the prevalence of use of prescribed medicines in Australian community samples. STUDY DESIGN AND SETTING: In this study, face-to-face interviews were carried out with random, representative samples of South Australian adults, aged ≥15 years. Data on self-reported use of prescribed medicines, most commonly reported categories of prescribed medicines and use of multiple medicines for common body systems were collected. It was not possible to distinguish between medicines prescribed for acute and chronic use. RESULTS: A total of 3015 respondents were interviewed in 2004 and 3034 in 2008, representing participation rates of 76% and 73%. There was no significant increase in the prevalence of use of ≥1 (46.8% vs 47.3%, p = 0.6) or ≥6 medicines (5.7% vs 5.5%, p = 0.7). In both years, the use of medicines was higher in women (56.7% vs 57.5%). On subgroup analyses, a significant reduction in the use of medicines was observed in respondents aged 15-24 (25.0% vs 18.5%, p = 0.01) and ≥65 years (87.7% vs 82.5%, p = 0.01), whereas use in those aged 35-44 years increased significantly (26.4% vs 33.6%, p = 0.01). The number of cardiovascular system agents (23.1% vs 24.6%, p = 0.20) and psychotropic medicines (9.8% vs 10.6%, p = 0.35) used by respondents remained unchanged while use of respiratory (7.2% vs 5.7%, p = 0.01) and musculoskeletal system medicines (8.7% vs 5.6% p= < 0.001) decreased significantly. CONCLUSIONS: In presenting what we believe is the first Australian population-based study to compare changes in prescribed medicines across the adult age spectrum, we highlight some key questions to ensure the quality use of medicines. Our findings identify a need to discuss de-prescribing, monitor practices to minimise adverse events and challenge if consumers and prescribers need to consider the costs to governments of medicines. Copyright © 2013 John Wiley & Sons, Ltd.
Kerena A Eckert; Zumin Shi; Anne W Taylor; Gary Wittert; Kay Price; Robert D Goldney
Related Documents :
7628113 - Role of clinical practice guidelines and clinical profiling in facilitating optimal lab...
22097003 - Evaluation of cattle bedding and grazing bmps in an agricultural watershed in alberta.
22896673 - Balancing tissue and tumor formation in regenerative medicine.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-21
Journal Detail:
Title:  Pharmacoepidemiology and drug safety     Volume:  -     ISSN:  1099-1557     ISO Abbreviation:  Pharmacoepidemiol Drug Saf     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9208369     Medline TA:  Pharmacoepidemiol Drug Saf     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 John Wiley & Sons, Ltd.
Population Research and Outcome Studies, Discipline of Medicine, University of Adelaide, Adelaide, South Australia, 5005, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Endocrinological issues and hormonal manipulation in children and men with Klinefelter syndrome.
Next Document:  Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate ...